TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:
CGEN) today announced that the Company will host a conference call
at 10:00 AM EST on Tuesday, February 10, 2015 to review fourth quarter
and year-end 2014 results. Compugen participants on the conference call
will include Martin Gerstel, Chairman; Dr. Anat Cohen-Dayag, President
and CEO; and Ari Krashin, CFO. The quarterly and year-end results will
be released on the Company’s website (www.cgen.com),
prior to the call.
To access the conference call, please dial 1-888-668-9141 from the US,
or +972-3-918-0609 internationally. The call will also be available via
live webcast through Compugen’s website, located at the following link.
A replay of the conference call will be available approximately two
hours after the completion of the live conference call. To access the
replay, please dial 1-888-782-4291 from the US or +972-3-925-5904
internationally. The replay will be available through February 12, 2015.
About Compugen
Compugen is a leading drug discovery company focused on monoclonal
antibodies and therapeutic proteins to address important unmet needs in
the fields of oncology and immunology. The Company utilizes a broad and
continuously growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine learning
systems and other computational biology capabilities for the in
silico (by computer) prediction and selection of novel drug target
candidates, which are then advanced in its Pipeline Program. The
discovery and development of monoclonal antibody therapeutic candidates
against selected Compugen-discovered novel target candidates is
performed by Compugen’s wholly-owned U.S. subsidiary located in South
San Francisco. The Company's business model includes collaborations
covering the further development and commercialization of product
candidates at various stages from its Pipeline Program and various forms
of research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or
other forms of revenue sharing. For additional information, please visit
Compugen's corporate website at www.cgen.com.